Who is sponsoring NCT07386886?

NCT07386886 is sponsored by Jian Zhang,MD.

What drugs are being tested in NCT07386886?

Interventions in NCT07386886: systematic therapy.

What condition does NCT07386886 study?

NCT07386886 studies Leptomeningeal Metastasis in Breast Cancer.

Is NCT07386886 still recruiting?

NCT07386886 is currently completed. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT07386886

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model for Breast Cancer Leptomeningeal Metastasis

Completed Last updated 4 February 2026

What this trial tests

trial testing systematic therapy in Leptomeningeal Metastasis in Breast Cancer in 403 participants. Completed in 26 January 2026.

Timeline

30 November 2013

Primary endpoint
30 November 2025

26 January 2026

Quick facts

Lead sponsor	Jian Zhang,MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	403
Start date	30 November 2013
Primary completion	30 November 2025
Estimated completion	26 January 2026

Drugs / interventions tested

systematic therapy — full drug profile →

Conditions studied

Leptomeningeal Metastasis in Breast Cancer — all drugs for Leptomeningeal Metastasis in Breast Cancer →

Sponsor

Jian Zhang,MD — full company profile →

Who can join

Adults 18 to 80, female only, with Leptomeningeal Metastasis in Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators conducted a large, multicenter retrospective study of patients with breast cancer leptomeningeal metastasis (BCLM), constituting one of the largest and most comprehensively curated cohorts to date. Data from 403 patients diagnosed between November 2013 and November 2025 were collected from three major academic centers. Detailed clinical, pathological, diagnostic, and treatment data were analyzed. Overall survival (OS) was evaluated, and independent prognostic factors were identified via Cox regression. A novel Breast Cancer Leptomeningeal Graded Prognostic Assessment (BC-LGPA) model was developed and validated for risk stratification.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of systematic therapy

Trials testing the same drug.

NCT06522542 — Gastric Cancer Complicated With Bleeding · not yet recruiting
NCT06178562 — Intermittent Oro-Esophageal Tube Feeding vs. Nasogastric Tube Feeding in Infants With Pierre Robin Syndrome · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07386886 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jian Zhang,MD
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07386886.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing